Laekna Company Description

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis in the People’s Republic of China, the United States of America, and South Korea.

The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity.

It also develops LAE109, LAE111, LAE112, LAE113, LAE122, LAE119, and LAE120 for the treatment of cancer; LAE118, a PI3Kα mutant-selective inhibitor; LAE103 for Sarcopenia; LAE123 to treat muscle and other disease indications; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis.

It has a collaboration with Eli Lilly and Company for the development of LAE102. Laekna, Inc. was incorporated in 2016 and is headquartered in Yuyao, China.

Laekna, Inc.

Country	Cayman Islands
Founded	2016
Industry	Biotechnology
Sector	Healthcare
Employees	86
CEO	Xiangyang Lu

Contact Details

Address: 3-2-467, 5 Xingbin Road Yuyao China
Website	laekna.com

Stock Details

Ticker Symbol	2105
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
SIC Code	2836

Key Executives

Name	Position
Dr. Xiangyang Lu Ph.D.	Chief Executive Officer and Executive Chairman
Kwok Keung Chau ACCA, C.F.A., HKICPA	Chief Financial Officer
Ling Xie	Senior Vice President of Head of Operation and Executive Director
Dr. Xiang-Ju Gu Ph.D.	Chief Scientific Officer and Executive Director
Chenyu Ke	Joint Company Secretary
Wing Nga Ho P.E.	Joint Company Secretary